

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Single Technology Appraisal

Niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [Review of TA673] (ID6403)

Provisional stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<u>Company</u> <ul style="list-style-type: none"> GlaxoSmithKline (niraparib) <u>Patient/carer groups</u> <ul style="list-style-type: none"> Black Health Agency for Equality Cancer 52 Cancer Black Care Eve Appeal Go Girls Helen Rollason Cancer Charity Independent Cancer Patients Voice Macmillan Cancer Support Maggie's Centres Marie Curie Ovacome Ovarian Cancer Action Robin Cancer Trust South Asian Health Foundation Specialised Healthcare Alliance Target Ovarian Cancer Tenovus Cancer Care Wellbeing of Women Women's Health Concern <u>Healthcare professional groups</u> <ul style="list-style-type: none"> Association of Cancer Physicians British Geriatrics Society British Gynaecological Cancer Society British Institute of Radiology British Psychosocial Oncology Society British Society of Urogynaecology Cancer Research UK National Forum of Gynaecological 	<u>General</u> <ul style="list-style-type: none"> All Wales Therapeutics and Toxicology Centre Allied Health Professionals Federation Board of Community Health Councils in Wales British National Formulary Care Quality Commission Department of Health, Social Services and Public Safety for Northern Ireland Healthcare Improvement Scotland Medicines and Healthcare products Regulatory Agency National Association of Primary Care National Pharmacy Association NHS Confederation Scottish Medicines Consortium Welsh Government Welsh Health Specialised Services Committee <u>Possible comparator companies</u> <ul style="list-style-type: none"> AstraZeneca (olaparib) Celltrion Healthcare (bevacizumab) Clovis Oncology (rucaparib) Dr. Reddy's Laboratories (bevacizumab) Organon Pharma (bevacizumab) Pfizer (bevacizumab) Roche (bevacizumab) Thornton & Ross (bevacizumab) Zentiva (bevacizumab) Pharma and (rucaparib)

Provisional stakeholder list for the evaluation of niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [Review of TA673] (ID6403)

Issue date: March 2025

© National Institute for Health and Care Excellence 2025. All rights reserved.

Page 1 of 3

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
<p>Oncology Nurses</p> <ul style="list-style-type: none"> • Royal College of General Practitioners • Royal College of Nursing • Royal College of Obstetricians & Gynaecologists • Royal College of Pathologists • Royal College of Physicians • Royal College of Radiologists • Royal Pharmaceutical Society • Royal Society of Medicine • Society and College of Radiographers • UK Clinical Pharmacy Association • UK Oncology Nursing Society <p><u>Others</u></p> <ul style="list-style-type: none"> • Department of Health and Social Care • NHS England 	<p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • Cochrane Gynaecological Cancer Group • Cochrane UK • Genomics England • Institute of Cancer Research • MRC Clinical Trials Unit • National Cancer Research Institute • National Institute for Health Research <p><u>Associated Public Health groups</u></p> <ul style="list-style-type: none"> • Public Health Wales • UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:

Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and the Welsh Government and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Provisional stakeholder list for the evaluation of niraparib for maintenance treatment of advanced ovarian, fallopian tube and peritoneal cancer after response to first-line platinum-based chemotherapy [Review of TA673] (ID6403)

Issue date: March 2025

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance, and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.